Paraneoplastic Neurologic Disorders (PND) malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Paraneoplastic Neurologic Disorders

Aliases & Descriptions for Paraneoplastic Neurologic Disorders:

Name: Paraneoplastic Neurologic Disorders 50
Pnd 50


Summaries for Paraneoplastic Neurologic Disorders

NIH Rare Diseases : 50 paraneoplastic neurologic disorders are a group of rare degenerative conditions that are triggered by a person's immune system response to a cancerous tumor. researchers believe these disorders occur when cancer-fighting antibodies or white blood cells known as t cells mistakenly attack normal cells in the nervous system. paraneoplastic neurologic disorders typically develop after mid-adulthood and are most common in people with lung, ovarian, lymphatic, or breast cancer. symptoms generally develop over a period of days to weeks and usually occur prior to tumor detection. these symptoms may include difficulty in walking and/or swallowing, loss of muscle tone, loss of fine motor coordination, slurred speech, memory loss, vision problems, sleep disturbances, dementia, seizures, sensory loss in the limbs, and vertigo. paraneoplastic neurologic disorders include lambert-eaton myasthenic syndrome, stiff-person syndrome, encephalomyelitis (inflammation of the brain and spinal cord), myasthenia gravis, cerebellar degeneration, limbic and/or brainstem encephalitis, neuromyotonia, and opsoclonus (involving eye movement) and sensory neuropathy. treatment involves treatment of the underlying tumor, immunotherapy, and supportive therapy. last updated: 6/9/2016

MalaCards based summary : Paraneoplastic Neurologic Disorders, also known as pnd, is related to stiff-person syndrome and paroxysmal ventricular fibrillation. An important gene associated with Paraneoplastic Neurologic Disorders is ZIC1 (Zic Family Member 1). The drugs Mitoxantrone and Interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and brain, and related phenotypes are behavior/neurological and nervous system

Related Diseases for Paraneoplastic Neurologic Disorders

Diseases related to Paraneoplastic Neurologic Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 stiff-person syndrome 10.8
2 paroxysmal ventricular fibrillation 9.8 ELAVL4 ZIC1
3 familial alzheimer-like prion disease 9.8 ZIC1 ZIC4
4 lung cancer 9.8
5 neuronitis 9.8
6 calciphylaxis cutis 9.7 ZIC1 ZIC4
7 encephalitis 9.6
8 limbic encephalitis 9.6
9 paroxysomal nonkinesigenic dyskinesia 9.4 AP3B2 ELAVL4 ZIC1 ZIC4

Graphical network of the top 20 diseases related to Paraneoplastic Neurologic Disorders:

Diseases related to Paraneoplastic Neurologic Disorders

Symptoms & Phenotypes for Paraneoplastic Neurologic Disorders

MGI Mouse Phenotypes related to Paraneoplastic Neurologic Disorders:

id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.26 AP3B2 ELAVL4 ZIC1 ZIC4
2 nervous system MP:0003631 8.92 AP3B2 ELAVL4 ZIC1 ZIC4

Drugs & Therapeutics for Paraneoplastic Neurologic Disorders

Drugs for Paraneoplastic Neurologic Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
3 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
4 Analgesics Phase 4
5 Topoisomerase Inhibitors Phase 4
6 Adjuvants, Immunologic Phase 4
7 Anti-Infective Agents Phase 4
8 Antiviral Agents Phase 4
9 Interferon-beta Phase 4
10 interferons Phase 4
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
4-Aminopyridine Approved Phase 3,Phase 2 504-24-5 1727
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
17 Antiemetics Phase 3
18 Anti-Inflammatory Agents Phase 3
19 Autonomic Agents Phase 3,Phase 1,Phase 2
20 Gastrointestinal Agents Phase 3
21 glucocorticoids Phase 3,Phase 1
22 Hormone Antagonists Phase 3,Phase 2,Phase 1
23 Hormones Phase 3,Phase 2,Phase 1
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
25 Methylprednisolone acetate Phase 3
26 Methylprednisolone Hemisuccinate Phase 3
27 Neuroprotective Agents Phase 3
28 Prednisolone acetate Phase 3
29 Prednisolone hemisuccinate Phase 3
30 Prednisolone phosphate Phase 3
31 Protective Agents Phase 3
32 3,4-diaminopyridine Phase 3,Phase 2
33 Potassium Channel Blockers Phase 3,Phase 2
34 Antirheumatic Agents Phase 3,Phase 2,Phase 1
35 Immunosuppressive Agents Phase 3
36 Antibodies Phase 3,Phase 2,Phase 1
37 Immunoglobulins Phase 3,Phase 2,Phase 1
38 Alkylating Agents Phase 3
39 Antineoplastic Agents, Alkylating Phase 3
40 Antineoplastic Agents, Hormonal Phase 3
41 BB 1101 Phase 3
42 Dexamethasone 21-phosphate Phase 3
43 Dexamethasone acetate Phase 3 1177-87-3
44 HIV Protease Inhibitors Phase 3
protease inhibitors Phase 3
46 gamma-Globulins Phase 3,Phase 2
47 Immunoglobulins, Intravenous Phase 3,Phase 2
48 Rho(D) Immune Globulin Phase 3,Phase 2
Ephedrine Approved Phase 1, Phase 2 299-42-3 9294
Pseudoephedrine Approved Phase 1, Phase 2 90-82-4 7028

Interventional clinical trials:

(show all 50)
id Name Status NCT ID Phase
1 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4
2 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4
3 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
4 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3
5 Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Recruiting NCT01868269 Phase 3
6 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Recruiting NCT02970162 Phase 3
7 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes Recruiting NCT02562066 Phase 3
8 Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome Available NCT01825395 Phase 3
9 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3
10 Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma Unknown status NCT00202930 Phase 2
11 Ephedrine for the Treatment of Congenital Myasthenia Unknown status NCT00541216 Phase 1, Phase 2
12 Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome Unknown status NCT01511978 Phase 2
13 MC-5A for Chemotherapy Induced Peripheral Neuropathy Completed NCT01261780 Phase 2
14 Effectiveness of Rituximab in Pediatric OMS Patients. Completed NCT00244361 Phase 1, Phase 2
15 Immunotherapy and Paraneoplastic Neurological Syndromes Active, not recruiting NCT02343211 Phase 2
16 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Active, not recruiting NCT02166346 Phase 2
17 IVIG Treatment for Refractory Immune-Related Adult Epilepsy Terminated NCT01545518 Phase 2
18 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2
19 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1
20 Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes Completed NCT01203592 Phase 1
21 Central Pain Study for ABX-1431 Recruiting NCT03138421 Phase 1
22 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1
23 A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis Unknown status NCT01623076
24 Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area Unknown status NCT02443350
25 Immunotherapy of the Paraneoplastic Syndromes Completed NCT00378326
26 Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers Completed NCT00608452
27 Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome Completed NCT00806182
28 The Effect of Diflunisal on Familial Transthyretin Amyloidosis Completed NCT01432587
29 Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome Completed NCT00004832
30 Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis Completed NCT01865578
31 Pregnancy Outcomes in Congenital Myasthenie Syndrome Completed NCT01474980
32 The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes Recruiting NCT00327236
33 National Registry for Egyptian Pediatric Neuromuscular Diseases Recruiting NCT02124616
34 Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study Recruiting NCT02144935
35 Congenital Muscle Disease Study of Patient and Family Reported Medical Information Recruiting NCT01403402
36 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS) Recruiting NCT00872950
37 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
38 Maintenance Plasma Exchange for Neuromyelitis Optica Active, not recruiting NCT01500681
39 Clinical Trial of a Serious Game for Individuals With SCI/D Active, not recruiting NCT02341950
40 Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China Active, not recruiting NCT02559089
41 Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients Available NCT02189720
42 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM) Available NCT02012933
43 Treatment of Lambert-Eaton Syndrome With 3,4 DAP Available NCT00704925
44 Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome Available NCT03062631
45 Treatment Use of 3,4-Diaminopyridine Available NCT01765140
46 Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine Available NCT00994916
47 Serum Auto-Antibodies in Neurological Diseases Enrolling by invitation NCT00704626
48 Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) Enrolling by invitation NCT02090725
49 Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP No longer available NCT01378546
50 Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome No longer available NCT01373333

Search NIH Clinical Center for Paraneoplastic Neurologic Disorders

Genetic Tests for Paraneoplastic Neurologic Disorders

Anatomical Context for Paraneoplastic Neurologic Disorders

MalaCards organs/tissues related to Paraneoplastic Neurologic Disorders:

Lung, Breast, Brain, T Cells, Eye, Spinal Cord, Testis

Publications for Paraneoplastic Neurologic Disorders

Articles related to Paraneoplastic Neurologic Disorders:

(show all 19)
id Title Authors Year
Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. ( 26109714 )
Diagnosis and management of paraneoplastic neurologic disorders. ( 23900965 )
Paraneoplastic Neurologic Disorders: A Brief Overview. ( 23264806 )
Paraneoplastic neurologic disorders in children. ( 21161703 )
Treatment of paraneoplastic neurologic disorders. ( 20842583 )
Update on paraneoplastic neurologic disorders. ( 20479279 )
Update on paraneoplastic neurologic disorders. ( 21572897 )
Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. ( 20065123 )
Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. ( 17113466 )
Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. ( 15477575 )
Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. ( 15007130 )
Paraneoplastic neurologic disorders: windows into neuronal function and tumor immunity. ( 14732616 )
Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. ( 12792307 )
Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. ( 10050892 )
The importance of defining the paraneoplastic neurologic disorders. ( 10362830 )
Mouse chromosomal locations of nine genes encoding homologs of human paraneoplastic neurologic disorder antigens. ( 9344654 )
Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. ( 8643438 )
Immune modulation of paraneoplastic neurologic disorders. ( 7788966 )
Clinical enigmas of paraneoplastic neurologic disorders. ( 7788978 )

Variations for Paraneoplastic Neurologic Disorders

Expression for Paraneoplastic Neurologic Disorders

Search GEO for disease gene expression data for Paraneoplastic Neurologic Disorders.

Pathways for Paraneoplastic Neurologic Disorders

GO Terms for Paraneoplastic Neurologic Disorders

Sources for Paraneoplastic Neurologic Disorders

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....